• Explore /
  • Poster
  • / A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Lecia V. Sequist

Massachusetts General Hospital, Boston, MA

Lecia V. Sequist , Ian Churchill Anderson , Nathan Demars , Enriqueta Felip , Wael A. Harb , Rudolf M. Huber , Art J. Kudla , Jean Kyung Lee , Sara Mathews , Ty McClure , Jorge J. Nieva , Maurice Perol , Frances A. Shepherd , Alexander I. Spira , Akos Gabor Czibere

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02387216

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS9110)

DOI

10.1200/JCO.2016.34.15_suppl.TPS9110

Abstract #

TPS9110

Poster Bd #

427b

Abstract Disclosures

Similar Posters

First Author: Lecia V. Sequist

First Author: Ruchit Shah

First Author: Benjamin Besse

First Author: Alexander I. Spira